-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer is one of the common malignant tumors threatening women's health and the leading cause of cancer-related deaths in women worldwide
breast cancer
The Journal of Clinical Oncology, a leading international oncology journal, reported the results of a phase III randomized controlled trial conducted by researchers at the University of Leeds, St.
(Image source: Journal of Clinical Oncology)
research method
research methodThe subjects of the study were cancer patients who started chemotherapy, most of them were breast cancer patients, and the rest were gynecological cancer and colorectal cancer patients
Colorectal Cancer Trials Registry: ISRCTN88520246.
manage
eRAPID group: On the basis of routine care, patients were also managed based on the ePAPID system
The eRAPID system combines ePRO symptom reporting with customized clinical algorithms to provide patients with automated, severity-based recommendations to support patients in self-management or contacting the hospital
Main outcome: Symptom control assessed at 6, 12, and 18 weeks (functional assessment of cancer care, physical fitness subscale FACT-PWB)
Quality of life QLQ-C30
Among the participants, there were 508 patients (73.
Subgroup analysis found a significant benefit in the non-metastatic group at week 6 (P = 0.
Results showed that real-time monitoring via the ePRO system improved physical health (weeks 6 and 12) and self-efficacy (week 18) in a primarily curative patient population without increasing hospital workload
Research Implications
Research ImplicationsThese findings demonstrate that remote real-time monitoring is feasible in routine cancer care, especially in the context of the COVID-19 pandemic; an alternative digital care model during therapeutic chemotherapy that can help cancer patients with mild to moderate symptoms Improve physical condition, reduce hospital visits, and even improve quality of life and long-term survival
COVID-19
In the future, the digital clinical trial (DCT) model will become more and more mature with continuous exploration
Research design
Original source:
Absolom K, Warrington L, Hudson E, Hewison J, Morris C, Holch P, Carter R, Gibson A, Holmes M, Clayton B, Rogers Z, McParland L, Conner M, Glidewell L, Woroncow B, Dawkins B, Dickinson S , Hulme C, Brown J, Velikova G.
Basch E, Leahy AB, Dueck AC.
leave a message here